Prognostic Significance Of HIF-1α Polymorphisms In Transitional Cell Carcinoma Of The Bladder
Main Category: Urology / NephrologyAlso Included In: Cancer / Oncology
Article Date: 15 Jun 2008 - 4:00 PDT
| Patient / Public: | ![]() |
5 (1 votes) |
| Healthcare Prof: | ![]() |
ORLANDO, FL (UroToday.com) - Recently, two single nucleotide polymorphisms in the hypoxia-inducible factor-1alpha (HIF-1α) gene, P582S and A588T were shown to cause significantly higher transcriptional activity than the wild type. A group of Japanese scientists investigated the association between the HIF-1α polymorphisms and the incidence and progression of transitional cell carcinoma of the bladder, and the relationship between the polymorphisms and the tissue vascular endothelial growth factor (VEGF) level or microvessel density (MVD).
A total of 219 patients with bladder cancer and 464 healthy native Japanese control subjects were enrolled. Tissue VEGF and HIF-1 α expression levels and the mean MVD were evaluated in 73 radical cystectomy specimens by immunohistochemistry.
The HIF-1α genotype did not significantly influence the incidence or disease status of bladder cancer. Among patients who underwent radical cystectomy, those with a variant Allele had significantly worse disease-free survival and (p=0.001) and disease-specific survival (p=0.006) than those without a variant allele. Multivariate analysis using a Cox proportional hazard model revealed that the presence of a variant allele was an independent predictor of disease-free survival (HR = 3.10, 95%CI = 1.38-6.99, p = 0.006). Although not statistically significant, the moderate/high expression levels of VEGF in tumor tissues were more frequently observed in patients with a HIF-1α variant allele (11/13, 84.6%) than in those without (33/60, 55%, p = 0.063).
They conclude that the HIF-1α polymorphisms may have a significant influence on the poor prognosis of the patients undergoing radical cystectomy for bladder cancer, while they seem to have no relation to the bladder cancer occurrence.
Presented by Junichi Nadaoka, MD, et al., at the Annual Meeting of the American Urological Association (AUA) - May 17 - 22, 2008. Orange County Convention Center - Orlando, Florida, USA.
Reported by UroToday.com Contributing Editor Christopher P. Evans, MD, FACS
UroToday - the only urology website with original content written by global urology key opinion leaders actively engaged in clinical practice.
To access the latest urology news releases from UroToday, go to: www.urotoday.com
Copyright © 2008 - UroToday
Visit our urology / nephrology section for the latest news on this subject.
MLA
14 Feb. 2012. <http://www.medicalnewstoday.com/releases/111299.php>
APA
http://www.medicalnewstoday.com/releases/111299.php.
Please note: If no author information is provided, the source is cited instead.
|
Rate this article: (Hover over the stars then click to rate) |
Patient / Public: |
or |
Health Professional: |
Add Your Opinion
Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
![]()
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.




